Spanish Biotech Star Oryzon Slumps After Roche Rejection
Barcelona-based Oryzon Genomics remains upbeat about the prospects for 'a first-in-class, best-in-class LSD1 inhibitor' for cancer even though Roche has walked away from what was a potentially lucrative partnership.
You may also be interested in...
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.